Recent Applications of Liposomes in Ophthalmic Drug Delivery

Abstract

Liposomal formulations were significantly explored over the last decade for the ophthalmic drug delivery applications. These formulations are mainly composed of phosphatidylcholine (PC) and other constituents such as cholesterol and lipid-conjugated hydrophilic polymers. Liposomes are biodegradable and biocompatible in nature. Current approaches for topical delivery of liposomes are focused on improving the corneal adhesion and permeation by incorporating various bioadhesive and penetration enhancing polymers. In the case of posterior segment disorders improvement in intravitreal half life and targeted drug delivery to the retina is achieved by liposomes. In this paper we have attempted to summarize the applications of liposomes in the field of ophthalmic drug delivery by citing numerous investigators over the last decade.

References 82

1. 1.

   Geroski DH, Edelhauser HF. Drug delivery for posterior segment eye disease. Investigative Ophthalmology and Visual Science. 2000;41(5):961-964.

   Not in our library

2. 2.

   Urtti A. Challenges and obstacles of ocular pharmacokinetics and drug delivery. Advanced Drug Delivery Reviews. 2006;58(11):1131-1135.

   Not in our library10.1016/j.addr.2006.07.027

3. 3.

   Mitra AK. Role of transporters in ocular drug delivery system. Pharmaceutical Research. 2009;26(5):1192-1196.

   Not in our library10.1007/s11095-009-9862-x

4. 4.

   Kaur IP, Kanwar M. Ocular preparations: the formulation approach. Drug Development and Industrial Pharmacy. 2002;28(5):473-493.

   Not in our library10.1081/ddc-120003445

5. 5.

   Wadhwa S, Paliwal R, Vyas SP. Nanocarriers in ocular drug delivery: an update review. Current Pharmaceutical Design. 2009;15(23):2724-2750.

   Not in our library10.2174/138161209788923886

6. 6.

   Bangham AD, Standish MM, Watkins JC. Diffusion of univalent ions across the lamellae of swollen phospholipids. Journal of Molecular Biology. 1965;13(1):238-252.

   Not in our library10.1016/s0022-2836(65)80093-6

7. 7.

   Kaur IP, Garg A, Singla AK, Aggarwal D. Vesicular systems in ocular drug delivery: an overview. International Journal of Pharmaceutics. 2004;269(1):1-14.

   Not in our library10.1016/j.ijpharm.2003.09.016

8. 8.

   Mainardes RM, Urban MCC, Cinto PO, et al. Colloidal carriers for ophthalmic drug delivery. Current Drug Targets. 2005;6(3):363-371.

   Not in our library10.2174/1389450053765914

9. 9.

   Elbayoumi TA, Torchilin VP. Current trends in liposome research. Methods in Molecular Biology. 2010;605:1-27.

   Not in our library10.1007/978-1-60327-360-2_1

10. 10.

    Li N, Zhuang C, Wang M, Sun X, Nie S, Pan W. Liposome coated with low molecular weight chitosan and its potential use in ocular drug delivery. International Journal of Pharmaceutics. 2009;379(1-2):131-138.

    Not in our library10.1016/j.ijpharm.2009.06.020

11. 11.

    Ding X, Alani WG, Robinson JR, Troy DB. extended-release and targeted drug delivery systems. Remington: The Science and Practice of Pharmacy. 2005.

    Not in our library

12. 12.

    Jesorka A, Orwar O. Liposomes: technologies and analytical applications. Annual Review of Analytical Chemistry. 2008;1(1):801-832.

    Not in our library10.1146/annurev.anchem.1.031207.112747

13. 13.

    Lian T, Ho RJY. Trends and developments in liposome drug delivery systems. Journal of Pharmaceutical Sciences. 2001;90(6):667-680.

    Not in our library10.1002/jps.1023

14. 14.

    Niesman MR. The use of liposomes as drug carriers in ophthalmology. Critical Reviews in Therapeutic Drug Carrier Systems. 1992;9(1):1-38.

    Not in our library

15. 15.

    Papahadjopoulos D, Jacobson K, Nir S, Isac T. Phase transitions in phospholipid vesicles. Fluorescence polarization and permeability measurements concerning the effect of temperature and cholesterol. Biochimica et Biophysica Acta. 1973;311(3):330-348.

    Not in our library10.1016/0005-2736(73)90314-3

16. 16.

    Guy RH, Hadgraft J, Taylor MJ, Kellaway IW. Release of non-electrolytes from liposomes. Journal of Pharmacy and Pharmacology. 1983;35(1):12-14.

    Not in our library10.1111/j.2042-7158.1983.tb04254.x

17. 17.

    Tsukada K, Ueda S, Okada R. Preparation of liposome-encapsulated anti-tumor drugs: relationship between lipophilicity of drugs and in vitro drug release. Chemical and Pharmaceutical Bulletin. 1984;32(5):1929-1935.

    Not in our library

18. 18.

    Zeng L, Wu X. Modeling the sustained release of lipophilic drugs from liposomes. Applied Physics Letters. 2010;97(7):3 pages.

    Not in our library

19. 19.

    Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nature Reviews Drug Discovery. 2005;4(2):145-160.

    Not in our library10.1038/nrd1632

20. 20.

    Bonacucina G, Cespi M, Misici-Falzi M, Palmieri GF. Colloidal soft matter as drug delivery system. Journal of Pharmaceutical Sciences. 2009;98(1):1-42.

    Not in our library10.1002/jps.21423

21. 21.

    Ruiz-Moreno JM, Montero JA, Arias L, et al. Photodynamic therapy in subfoveal and juxtafoveal idiopathic and postinflammatory choroidal neovascularization. Acta Ophthalmologica Scandinavica. 2006;84(6):743-748.

    Not in our library10.1111/j.1600-0420.2006.00691.x

22. 22.

    Lazzeri S, Figus M, Di Bartolo E, Rizzo S, Nardi M. Verteporfin photodynamic therapy for retinal hemangioblastoma associated with Von Hippel-Lindau Disease in a 9-year-old child.

    Not in our library10.1111/j.1442-9071.2010.02428.x

23. 23.

    Sachdeva R, Dadgostar H, Kaiser PK, Sears JE, Singh AD. Verteporfin photodynamic therapy of six eyes with retinal capillary haemangioma. Acta Ophthalmologica. 2010;88(8):e334-e340.

    Not in our library10.1111/j.1755-3768.2010.02008.x

24. 24.

    Chakravdrthy U, Soubrane G, Bandello F, et al. Evolving European guidance on the medical management of neovascular age related macular degeneration. British Journal of Ophthalmology. 2006;90(9):1188-1196.

    Not in our library10.1136/bjo.2005.082255

25. 25.

    Rostaporfin: PhotoPoint SnET2, purlytin, Sn(IV) etiopurpurin, SnET2, tin ethyl etiopurpurin. Drugs in R and D. 2004;5(1):58-61.

    Not in our library10.2165/00126839-200405010-00013

26. 26.

    Shen Y, Tu J. Preparation and ocular pharmacokinetics of ganciclovir liposomes. AAPS Journal. 2007;9(3):E371-E377.

    Not in our library10.1208/aapsj0903044

27. 27.

    Hosny KM. Ciprofloxacin as ocular liposomal hydrogel. AAPS PharmSciTech. 2010;11(1):241-246.

    Not in our library10.1208/s12249-009-9373-4

28. 28.

    Danion A, Arsenault I, Vermette P. Antibacterial activity of contact lenses bearing surface-immobilized layers of intact liposomes loaded with levofloxacin. Journal of Pharmaceutical Sciences. 2007;96(9):2350-2363.

    Not in our library10.1002/jps.20871

29. 29.

    Cortesi R, Argnani R, Esposito E, et al. Cationic liposomes as potential carriers for ocular administration of peptides with anti-herpetic activity. International Journal of Pharmaceutics. 2006;317(1):90-100.

    Not in our library10.1016/j.ijpharm.2006.02.050

30. 30.

    Hathout RM, Mansour S, Mortada ND, Guinedi AS. Liposomes as an ocular delivery system for acetazolamide: in vitro and in vivo studies. AAPS PharmSciTech. 2007;8(1, article 1).

    Not in our library10.1208/pt0804080

31. 31.

    Zhang R, He R, Qian J, Guo J, Xue K, Yuan YF. Treatment of experimental autoimmune uveoretinitis with intravitreal injection of tacrolimus (FK506) encapsulated in liposomes. Investigative Ophthalmology & Visual Science. 2010;51(7):3575-3582.

    Not in our library10.1167/iovs.09-4373

32. 32.

    Camelo S, Lajavardi L, Bochot A, et al. Ocular and systemic bio-distribution of rhodamine-conjugated liposomes loaded with VIP injected into the vitreous of Lewis rats. Molecular Vision. 2007;13:2263-2274.

    Not in our library

33. 33.

    Fukushima A, Ozaki A, Ishida W, van Rooijen N, Fukata K, Ueno H. Suppression of macrophage infiltration into the conjunctiva by clodronate liposomes in experimental immune-mediated blepharoconjunctivitis. Cell Biology International. 2005;29(4):277-286.

    Not in our library10.1016/j.cellbi.2004.12.011

34. 34.

    Kawakami S, Harada A, Sakanaka K, et al. In vivo gene transfection via intravitreal injection of cationic liposome/plasmid DNA complexes in rabbits. International Journal of Pharmaceutics. 2004;278(2):255-262.

    Not in our library10.1016/j.ijpharm.2004.03.013

35. 35.

    Peeters L, Sanders NN, Braeckmans K, et al. Vitreous: a barrier to nonviral ocular gene therapy. Investigative Ophthalmology and Visual Science. 2005;46(10):3553-3561.

    Not in our library10.1167/iovs.05-0165

36. 36.

    Schaeffer HE, Krohn DL. Liposomes in topical drug delivery. Investigative Ophthalmology and Visual Science. 1982;22(2):220-227.

    Not in our library

37. 37.

    Singh K, Mezei M. Liposomal ophthalmic drug delivery system. I. Triamcinolone acetonide. International Journal of Pharmaceutics. 1983;16(3):339-344.

    Not in our library

38. 38.

    Singh K, Mezei M. Liposomal ophthalmic drug delivery system. II. Dihydrostreptomycin sulfate. International Journal of Pharmaceutics. 1984;19(3):263-269.

    Not in our library

39. 39.

    Fitzgerald P, Hadgraft J, Wilson CG. A gamma scintigraphic evaluation of the precorneal residence of liposomal formulations in the rabbit. Journal of Pharmacy and Pharmacology. 1987;39(6):487-490.

    Not in our library10.1111/j.2042-7158.1987.tb03428.x

40. 40.

    Aiba S. Studies on chitosan: 4. Lysozymic hydrolysis of partially N-acetylated chitosans. International Journal of Biological Macromolecules. 1992;14(4):225-228.

    Not in our library10.1016/s0141-8130(05)80032-7

41. 41.

    Tomihata K, Ikada Y. In vitro and in vivo degradation of films of chitin and its deacetylated derivatives. Biomaterials. 1997;18(7):567-575.

    Not in our library10.1016/s0142-9612(96)00167-6

42. 42.

    Mehanna MM, Elmaradny HA, Samaha MW. Mucoadhesive liposomes as ocular delivery system: physical, microbiological, and in vivo assessment. Drug Development and Industrial Pharmacy. 2010;36(1):108-118.

    Not in our library10.3109/03639040903099751

43. 43.

    Zhang J, Wang S. Topical use of Coenzyme Q10-loaded liposomes coated with trimethyl chitosan: tolerance, precorneal retention and anti-cataract effect. International Journal of Pharmaceutics. 2009;372(1-2):66-75.

    Not in our library10.1016/j.ijpharm.2009.01.001

44. 44.

    Diebold Y, Jarrín M, Sáez V, et al. Ocular drug delivery by liposome-chitosan nanoparticle complexes (LCS-NP). Biomaterials. 2007;28(8):1553-1564.

    Not in our library10.1016/j.biomaterials.2006.11.028

45. 45.

    de Campos AM, Sánchez A, Alonso MJ. Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A. International Journal of Pharmaceutics. 2001;224(1-2):159-168.

    Not in our library10.1016/s0378-5173(01)00760-8

46. 46.

    Law SL, Huang KJ, Chiang CH. Acyclovir-containing liposomes for potential ocular delivery Corneal penetration and absorption. Journal of Controlled Release. 2000;63(1-2):135-140.

    Not in our library10.1016/s0168-3659(99)00192-3

47. 47.

    Chetoni P, Rossi S, Burgalassi S, Monti D, Mariotti S, Saettone MF. Comparison of liposome-encapsulated acyclovir with acyclovir ointment: ocular pharmacokinetics in rabbits. Journal of Ocular Pharmacology and Therapeutics. 2004;20(2):169-177.

    Not in our library10.1089/108076804773710849

48. 48.

    Zhang J, Guan P, Wang T, Chang D, Jiang T, Wang S. Freeze-dried liposomes as potential carriers for ocular administration of cytochrome c against selenite cataract formation. Journal of Pharmacy and Pharmacology. 2009;61(9):1171-1178.

    Not in our library10.1211/jpp/61.09.0006

49. 49.

    Habib FS, Fouad EA, Abdel-Rhaman MS, Fathalla D. Liposomes as an ocular delivery system of fluconazole: in-vitro studies. Acta Ophthalmologica. 2010;88(8):901-904.

    Not in our library10.1111/j.1755-3768.2009.01584.x

50. 50.

    Guzek JP, Roosenberg JM, Gano DL, Wessels IF. The effect of vehicle on corneal penetration of triturated ketoconazole and itraconazole. Ophthalmic Surgery and Lasers. 1998;29(11):926-929.

    Not in our library

51. 51.

    Budai L, Hajdú M, Budai M, et al. Gels and liposomes in optimized ocular drug delivery: studies on ciprofloxacin formulations. International Journal of Pharmaceutics. 2007;343(1-2):34-40.

    Not in our library10.1016/j.ijpharm.2007.04.013

52. 52.

    Merino S, Vázquez JL, Doménech JL, et al. Fluoroquinolone-biomembrane interaction at the DPPC/PG lipid-bilayer interface. Langmuir. 2002;18(8):3288-3292.

    Not in our library

53. 53.

    Budai M, Pallaghy R, Szabó Zs, Zimmer A, Gróf P. Molecular interactions in lomefloxacin—liposome systems. Cellular and Molecular Biology Letters. 2005;10(70).

    Not in our library

54. 54.

    Mu X, Zhong Z. Preparation and properties of poly(vinyl alcohol)-stabilized liposomes. International Journal of Pharmaceutics. 2006;318(1-2):55-61.

    Not in our library10.1016/j.ijpharm.2006.03.016

55. 55.

    Xie AF, Granick S. Phospholipid membranes as substrates for polymer adsorption. Nature Materials. 2002;1(2):129-133.

    Not in our library10.1038/nmat738

56. 56.

    Abdelbary G. Ocular ciprofloxacin hydrochloride mucoadhesive chitosan-coated liposomes. Pharmaceutical Development and Technology. 2009;16(1):44-56.

    Not in our library10.3109/10837450903479988

57. 57.

    Felt O, Furrer P, Mayer JM, Plazonnet B, Buri P, Gurny R. Topical use of chitosan in ophthalmology: tolerance assessment and evaluation of precorneal retention. International Journal of Pharmaceutics. 1999;180(2):185-193.

    Not in our library10.1016/s0378-5173(99)00003-4

58. 58.

    Craig JP, Purslow C, Murphy PJ, Wolffsohn JSW. Effect of a liposomal spray on the pre-ocular tear film. Contact Lens and Anterior Eye. 2010;33(2):83-87.

    Not in our library10.1016/j.clae.2009.12.007

59. 59.

    Afouna MI, Khattab IS, Reddy IK. Preparation and characterization of demeclocycline liposomal formulations and assessment of their intraocular pressure-lowering effects. Cutaneous and Ocular Toxicology. 2005;24(2):111-124.

    Not in our library10.1081/cus-200059582

60. 60.

    Monem AS, Ali FM, Ismail MW. Prolonged effect of liposomes encapsulating pilocarpine HCl in normal and glaucomatous rabbits. International Journal of Pharmaceutics. 2000;198(1):29-38.

    Not in our library10.1016/s0378-5173(99)00348-8

61. 61.

    Lesher GA, Gunderson GG. Continuous drug delivery through the use of disposable contact lenses. Optometry and Vision Science. 1993;70(12):1012-1018.

    Not in our library10.1097/00006324-199312000-00004

62. 62.

    Danion A, Brochu H, Martin Y, Vermette P. Fabrication and characterization of contact lenses bearing surface-immobilized layers of intact liposomes. Journal of Biomedical Materials Research A. 2007;82(1):41-51.

    Not in our library10.1002/jbm.a.31147

63. 63.

    Mahmoud SS, Gehmam JD, Azzopardi K, Robins-Browne RM, Separovic F. Liposomal phospholipid preparations of chloramphenicol for ophthalmic applications. Journal of Pharmaceutical Sciences. 2008;97(7):2691-2701.

    Not in our library10.1002/jps.21201

64. 64.

    Pleyer U, Groth D, Hinz B, et al. Efficiency and toxicity of liposome-mediated gene transfer to corneal endothelial cells. Experimental Eye Research. 2001;73(1):1-7.

    Not in our library10.1006/exer.2001.1005

65. 65.

    Teshima M, Kawakami S, Nishida K, et al. Prednisolone retention in integrated liposomes by chemical approach and pharmaceutical approach. Journal of Controlled Release. 2004;97(2):211-218.

    Not in our library10.1016/j.jconrel.2004.03.011

66. 66.

    Kawakami S, Yamamura K, Mukai T, et al. Sustained ocular delivery of tilisolol to rabbits after topical administration or intravitreal injection of lipophilic prodrug incorporated in liposomes. Journal of Pharmacy and Pharmacology. 2001;53(8):1157-1161.

    Not in our library10.1211/0022357011776423

67. 67.

    Peyman GA, Schulman JA, Khoobehi B, Alkan HM, Tawakol ME, Mani H. Toxicity and clearance of a combination of liposome-encapsulated ganciclovir and trifluridine. Retina. 1989;9(3):232-236.

    Not in our library

68. 68.

    Alghadyan AA, Peyman GA, Khoobehi B, Milner S, Liu KR. Liposome-bound cyclosporine: clearance after intravitreal injection. International Ophthalmology. 1988;12(2):109-112.

    Not in our library10.1007/bf00137135

69. 69.

    Barza M, Stuart M, Szoka F. Effect of size and lipid composition on the pharmacokinetics of intravitreal liposomes. Investigative Ophthalmology and Visual Science. 1987;28(5):893-900.

    Not in our library

70. 70.

    Ebrahim S, Peyman GA, Lee PJ. Applications of liposomes in ophthalmology. Survey of Ophthalmology. 2005;50(2):167-182.

    Not in our library10.1016/j.survophthal.2004.12.006

71. 71.

    Taylor AW, Streilein JW, Cousins SW. Immunoreactive vasoactive intestinal peptide contributes to the immunosuppressive activity of normal aqueous humor. Journal of Immunology. 1994;153(3):1080-1086.

    Not in our library

72. 72.

    Lajavardi L, Bochot A, Camelo S, et al. Downregulation of endotoxin-induced uveitis by intravitreal injection of vasoactive intestinal peptide encapsulated in liposomes. Investigative Ophthalmology and Visual Science. 2007;48(7):3230-3238.

    Not in our library10.1167/iovs.06-1305

73. 73.

    Camelo S, Lajavardi L, Bochot A, et al. Drainage of fluorescent liposomes from the vitreous to cervical lymph nodes via conjunctival lymphatics. Ophthalmic Research. 2008;40(3-4):145-150.

    Not in our library10.1159/000119866

74. 74.

    Abrishami M, Ganavati SZ, Soroush D, Rouhbakhsh M, Jaafari MR, Malaekeh-Nikouei B. Preparation, characterization, and in vivo evaluation of nanoliposomes-encapsulated bevacizumab (avastin) for intravitreal administration. Retina. 2009;29(5):699-703.

    Not in our library10.1097/iae.0b013e3181a2f42a

75. 75.

    Velpandian T, Narayanan K, Nag TC, Ravi AK, Gupta SK. Retinal toxicity of intravitreally injected plain and liposome formulation of fluconazole in rabbit eye. Indian Journal of Ophthalmology. 2006;54(4):237-240.

    Not in our library10.4103/0301-4738.27947

76. 76.

    Cheng L, Hostetler KY, Chaidhawangul S, et al. Intravitreal toxicology and duration of efficacy of a novel antiviral lipid prodrug of ganciclovir in liposome formulation. Investigative Ophthalmology and Visual Science. 2000;41(6):1523-1532.

    Not in our library

77. 77.

    Bochot A, Fattal E, Boutet V, et al. Intravitreal delivery of oligonucleotides by sterically stabilized liposomes. Investigative Ophthalmology and Visual Science. 2002;43(1):253-259.

    Not in our library

78. 78.

    Gupta SK, Velpandian T, Dhingra N, Jaiswal J. Intravitreal pharmacokinetics of plain and liposome-entrapped fluconazole in rabbit eyes. Journal of Ocular Pharmacology and Therapeutics. 2000;16(6):511-518.

    Not in our library10.1089/jop.2000.16.511

79. 79.

    Raghava S, Hammond M, Kompella UB. Periocular routes for retinal drug delivery. Expert Opinion on Drug Delivery. 2004;1(1):99-114.

    Not in our library10.1517/17425247.1.1.99

80. 80.

    Assil KK, Frucht-Perry J, Ziegler E, Schanzlin DJ, Schneiderman T, Weinreb RN. Tobramycin liposomes: single subconjunctival therapy of pseudomonal keratitis. Investigative Ophthalmology and Visual Science. 1991;32(13):3216-3220.

    Not in our library

81. 81.

    Moon JW, Song YK, Jee JP, Kim CK, Choung HK, Hwang JM. Effect of subconjunctivally injected, liposome-bound, low-molecular-weight heparin on the absorption rate of subconjunctival hemorrhage in rabbits. Investigative Ophthalmology and Visual Science. 2006;47(9):3968-3974.

    Not in our library10.1167/iovs.05-1345

82. 82.

    Baek SH, Park SJ, Jin SE, Kim JK, Kim CK, Hwang JM. Subconjunctivally injected, liposome-encapsulated streptokinase enhances the absorption rate of subconjunctival hemorrhages in rabbits. European Journal of Pharmaceutics and Biopharmaceutics. 2009;72(3):546-551.

    Not in our library10.1016/j.ejpb.2009.03.010

Cited by papers we hold 2

• SPC Liposomes as Possible Delivery Systems for Improving Bioavailability of the Natural Sesquiterpene β-Caryophyllene: Lamellarity and Drug-Loading as Key Features for a Rational Drug Delivery Design · 2018
  Not checked
• Current Trends in Development of Liposomes for Targeting Bacterial Biofilms · 2016
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.